DK3253875T3 - Tau-antisense-oligomerer og anvendelser deraf - Google Patents
Tau-antisense-oligomerer og anvendelser deraf Download PDFInfo
- Publication number
- DK3253875T3 DK3253875T3 DK16706943.4T DK16706943T DK3253875T3 DK 3253875 T3 DK3253875 T3 DK 3253875T3 DK 16706943 T DK16706943 T DK 16706943T DK 3253875 T3 DK3253875 T3 DK 3253875T3
- Authority
- DK
- Denmark
- Prior art keywords
- antisense oligomers
- tau antisense
- tau
- oligomers
- antisense
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562112058P | 2015-02-04 | 2015-02-04 | |
US201562156684P | 2015-05-04 | 2015-05-04 | |
US201562237922P | 2015-10-06 | 2015-10-06 | |
US201562238941P | 2015-10-08 | 2015-10-08 | |
US201662279614P | 2016-01-15 | 2016-01-15 | |
US201662279612P | 2016-01-15 | 2016-01-15 | |
US201662279610P | 2016-01-15 | 2016-01-15 | |
PCT/US2016/016646 WO2016126995A1 (en) | 2015-02-04 | 2016-02-04 | Tau antisense oligomers and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3253875T3 true DK3253875T3 (da) | 2020-04-14 |
Family
ID=55443327
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK16706943.4T DK3253875T3 (da) | 2015-02-04 | 2016-02-04 | Tau-antisense-oligomerer og anvendelser deraf |
Country Status (24)
Country | Link |
---|---|
US (3) | US10799523B2 (da) |
EP (2) | EP3253875B1 (da) |
JP (1) | JP2018505676A (da) |
KR (1) | KR20180016970A (da) |
CN (1) | CN107922946A (da) |
AU (1) | AU2016215155A1 (da) |
BR (1) | BR112017016663A2 (da) |
CA (1) | CA2975525A1 (da) |
CL (1) | CL2017001956A1 (da) |
CO (1) | CO2017009008A2 (da) |
CR (1) | CR20170359A (da) |
DK (1) | DK3253875T3 (da) |
HK (1) | HK1248276A1 (da) |
IL (1) | IL253730A0 (da) |
MA (1) | MA41586A (da) |
MX (1) | MX2017010066A (da) |
PE (1) | PE20171766A1 (da) |
PH (1) | PH12017550069A1 (da) |
RU (1) | RU2017127609A (da) |
SG (1) | SG11201706293XA (da) |
TW (1) | TW201641691A (da) |
UY (1) | UY36550A (da) |
WO (1) | WO2016126995A1 (da) |
ZA (1) | ZA201705119B (da) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010270714B2 (en) | 2009-07-06 | 2015-08-13 | Wave Life Sciences Ltd. | Novel nucleic acid prodrugs and methods use thereof |
US10428019B2 (en) | 2010-09-24 | 2019-10-01 | Wave Life Sciences Ltd. | Chiral auxiliaries |
EP2734208B1 (en) | 2011-07-19 | 2017-03-01 | Wave Life Sciences Ltd. | Methods for the synthesis of functionalized nucleic acids |
JP6492003B2 (ja) | 2012-03-30 | 2019-03-27 | ワシントン・ユニバーシティWashington University | 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法 |
CN107011400B (zh) | 2012-07-13 | 2021-05-25 | 波涛生命科学有限公司 | 不对称辅助基团 |
TWI657819B (zh) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
JP6772156B2 (ja) | 2015-02-04 | 2020-10-21 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 治療用分子を選択する方法 |
JOP20200228A1 (ar) * | 2015-12-21 | 2017-06-16 | Novartis Ag | تركيبات وطرق لخفض تعبير البروتين tau |
JOP20190065A1 (ar) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | مركبات وطرق لتقليل التعبير عن tau |
EP3737761A1 (en) * | 2018-01-12 | 2020-11-18 | Bristol-Myers Squibb Company | Antisense oligonucleotides targeting alpha-synuclein and uses thereof |
KR20200108315A (ko) * | 2018-02-09 | 2020-09-17 | 제넨테크, 인크. | Tmem106b의 발현을 조절하기 위한 올리고뉴클레오티드 |
EP3752612A4 (en) | 2018-02-12 | 2021-11-10 | Ionis Pharmaceuticals, Inc. | MODIFIED COMPOUNDS AND USES THEREOF |
AU2019233612A1 (en) * | 2018-03-13 | 2020-09-10 | Janssen Pharmaceutica Nv | Modified oligonucleotides for use in treatment of tauopathies |
US11613554B2 (en) | 2018-04-13 | 2023-03-28 | Bristol-Myers Squibb Company | Phosphorous (V)-based reagents, processes for the preparation thereof, and their use in making stereo-defined organophoshorous (V) compounds |
JP7379387B2 (ja) | 2018-06-05 | 2023-11-14 | エフ. ホフマン-ラ ロシュ アーゲー | Atxn2発現を制御するためのオリゴヌクレオチド |
SG11202012759XA (en) * | 2018-07-03 | 2021-01-28 | Hoffmann La Roche | Oligonucleotides for modulating tau expression |
CN113906139A (zh) * | 2019-04-03 | 2022-01-07 | 百时美施贵宝公司 | Angptl2反义寡核苷酸及其用途 |
US11286485B2 (en) | 2019-04-04 | 2022-03-29 | Hoffmann-La Roche Inc. | Oligonucleotides for modulating ATXN2 expression |
CN113785060A (zh) | 2019-04-04 | 2021-12-10 | 豪夫迈·罗氏有限公司 | 用于调节atxn2表达的寡核苷酸 |
JP7155302B2 (ja) | 2019-06-06 | 2022-10-18 | エフ.ホフマン-ラ ロシュ アーゲー | Atxn3を標的とするアンチセンスオリゴヌクレオチド |
US20210077421A1 (en) * | 2019-09-17 | 2021-03-18 | Zynerba Pharmaceuticals, Inc. | Treatment of syngap1 encephalopathy |
WO2021249993A1 (en) | 2020-06-09 | 2021-12-16 | Roche Innovation Center Copenhagen A/S | Guanosine analogues for use in therapeutic polynucleotides |
WO2022117745A1 (en) | 2020-12-03 | 2022-06-09 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
WO2022117747A2 (en) | 2020-12-03 | 2022-06-09 | F. Hoffmann-La Roche Ag | Antisense oligonucleotides targeting atxn3 |
WO2022125984A1 (en) * | 2020-12-11 | 2022-06-16 | Eisai R&D Management Co., Ltd. | Tau-targeting oligonucleotide gapmers |
JP2024506709A (ja) * | 2021-02-17 | 2024-02-14 | キュー-ステート バイオサイエンシーズ, インコーポレイテッド | Ube3aアンチセンス治療剤 |
WO2023278436A1 (en) * | 2021-06-29 | 2023-01-05 | Shape Therapeutics Inc. | Engineered guide rnas and polynucleotides |
WO2023217437A1 (en) * | 2022-05-13 | 2023-11-16 | Julius-Maximilians-Universität Würzburg | Method and molecules for reducing axonal tau protein accumulation through blocking of hnrnp r-mediated mapt mrna transport for treatment of alzheimer's disease |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
US5157021A (en) | 1985-03-15 | 1992-10-20 | Novo Nordisk A/S | Insulin derivatives and pharmaceutical preparations containing these derivatives |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US5264423A (en) * | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
US5648273A (en) | 1989-12-27 | 1997-07-15 | The United States Of America, As Represented By The Department Of Health And Human Services | Hepatic growth factor receptor is the MET proto-oncogene |
US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
US5453491A (en) | 1990-09-11 | 1995-09-26 | Kiyoshi Takatsu | Murine interleukin-5 receptor |
US5271941A (en) * | 1990-11-02 | 1993-12-21 | Cho Chung Yoon S | Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
US6582908B2 (en) * | 1990-12-06 | 2003-06-24 | Affymetrix, Inc. | Oligonucleotides |
WO1992018628A1 (en) | 1991-04-19 | 1992-10-29 | Schering Corporation | Subunit of the human interleukin-3 receptor |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US5227158A (en) | 1991-06-10 | 1993-07-13 | Genentech, Inc. | Method of stimulating hepatocyte proliferation by administration of hepatocyte growth factor and gamma-interferon |
US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
GB9506197D0 (en) * | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
US5686292A (en) | 1995-06-02 | 1997-11-11 | Genentech, Inc. | Hepatocyte growth factor receptor antagonist antibodies and uses thereof |
EP1382679A3 (en) | 1995-09-08 | 2004-11-10 | Genentech, Inc. | Vascular Endothelial Growth Factor Related Protein (VRP) Antagonists |
JP2000515735A (ja) | 1996-07-03 | 2000-11-28 | ジェネンテック インコーポレーテッド | 肝細胞成長因子レセプターアゴニスト |
US6159462A (en) | 1996-08-16 | 2000-12-12 | Genentech, Inc. | Uses of Wnt polypeptides |
GB9812127D0 (en) | 1998-06-06 | 1998-08-05 | Univ Glasgow | Detection of neural activity |
US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
ATE407949T1 (de) | 1998-12-30 | 2008-09-15 | Beth Israel Hospital | Charakterisierung der proteinfamilie von soc/crac kalziumkanälen |
PT1141015E (pt) | 1999-01-06 | 2009-10-13 | Genentech Inc | Variantes mutantes do factor de crescimento do tipo insulina (igf)i |
PT1141014E (pt) | 1999-01-06 | 2005-04-29 | Genentech Inc | Variante mutante do factor de crescimento semelhante a insulina (igf-i) |
US6617442B1 (en) | 1999-09-30 | 2003-09-09 | Isis Pharmaceuticals, Inc. | Human Rnase H1 and oligonucleotide compositions thereof |
DE60323231D1 (de) * | 2002-07-12 | 2008-10-09 | Axon Neuroscience | Verkürzte tau proteine |
AU2003281969B2 (en) | 2002-11-18 | 2011-01-27 | Roche Innovation Center Copenhagen A/S | Amino-LNA, thio-LNA and alpha-L-oxy-LN |
JP2006518197A (ja) | 2003-02-10 | 2006-08-10 | サンタリス・ファルマ・アクティーゼルスカブ | ラス発現の改変のためのオリゴマー化合物 |
US20050074801A1 (en) | 2003-09-09 | 2005-04-07 | Monia Brett P. | Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry |
US20050053981A1 (en) | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
US7919472B2 (en) | 2004-09-17 | 2011-04-05 | Isis Pharmaceuticals, Inc. | Enhanced antisense oligonucleotides |
WO2007031091A2 (en) | 2005-09-15 | 2007-03-22 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of p21 ras expression |
CA2640171C (en) | 2006-01-27 | 2014-10-28 | Isis Pharmaceuticals, Inc. | 6-modified bicyclic nucleic acid analogs |
AU2007258117B2 (en) | 2006-05-05 | 2013-05-30 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating gene expression |
ES2389737T3 (es) | 2006-05-11 | 2012-10-31 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en 5' |
US9550988B2 (en) | 2006-10-18 | 2017-01-24 | Ionis Pharmaceuticals, Inc. | Antisense compounds |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
WO2008150729A2 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
US8278283B2 (en) | 2007-07-05 | 2012-10-02 | Isis Pharmaceuticals, Inc. | 6-disubstituted or unsaturated bicyclic nucleic acid analogs |
WO2009067647A1 (en) | 2007-11-21 | 2009-05-28 | Isis Pharmaceuticals, Inc. | Carbocyclic alpha-l-bicyclic nucleic acid analogs |
WO2009090182A1 (en) | 2008-01-14 | 2009-07-23 | Santaris Pharma A/S | C4'-substituted - dna nucleotide gapmer oligonucleotides |
EP2265627A2 (en) | 2008-02-07 | 2010-12-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
US8846639B2 (en) | 2008-04-04 | 2014-09-30 | Isis Pharmaceutical, Inc. | Oligomeric compounds comprising bicyclic nucleosides and having reduced toxicity |
US9290534B2 (en) | 2008-04-04 | 2016-03-22 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds having at least one neutrally linked terminal bicyclic nucleoside |
EP2356129B1 (en) | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
CN101812127B (zh) * | 2009-02-19 | 2013-03-06 | 中国科学技术大学 | 微管结合蛋白及其编码基因与应用 |
US20100275274A1 (en) * | 2009-04-28 | 2010-10-28 | National Yang-Ming University | Mouse model for depression, schizophrenia and alzheimer's disease |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
WO2011048125A1 (en) | 2009-10-20 | 2011-04-28 | Santaris Pharma A/S | Oral delivery of therapeutically effective lna oligonucleotides |
US8779118B2 (en) | 2010-01-11 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
EP2902811B1 (en) | 2010-04-21 | 2019-04-17 | Vanderlande APC Inc. | Method and system for use in performing security screening |
EP3467109A1 (en) | 2011-02-08 | 2019-04-10 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US8778884B2 (en) | 2011-05-26 | 2014-07-15 | Fondazione Salvatore Maugeri Clinica del Lavora e Della Riabilitazione | Glioprotectant peptide for use in the treatment of amyotrophic lateral sclerosis (ALS) and methods related thereto |
US9243291B1 (en) | 2011-12-01 | 2016-01-26 | Isis Pharmaceuticals, Inc. | Methods of predicting toxicity |
JP6492003B2 (ja) | 2012-03-30 | 2019-03-27 | ワシントン・ユニバーシティWashington University | 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法 |
EP3336189A1 (en) | 2012-04-20 | 2018-06-20 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
US20160138014A1 (en) | 2012-10-12 | 2016-05-19 | Isis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
WO2014064187A1 (en) * | 2012-10-24 | 2014-05-01 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | A microtubuli-modifying compound |
US9014359B1 (en) | 2013-01-11 | 2015-04-21 | Time Warner Cable Enterprises Llc | Generation of phone number lists and call filtering |
AU2014236156C1 (en) | 2013-03-14 | 2020-12-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating Tau expression |
JP2016523980A (ja) | 2013-07-11 | 2016-08-12 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | タウ発現を抑制するマイクロrna |
TWI657819B (zh) * | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | 用於調節τ蛋白表現之組合物 |
WO2016019063A1 (en) | 2014-07-29 | 2016-02-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating tau expression |
JP6350987B2 (ja) | 2014-08-04 | 2018-07-04 | 本田技研工業株式会社 | GHファミリー3に属する耐熱性β―キシロシダーゼ |
-
2016
- 2016-02-04 SG SG11201706293XA patent/SG11201706293XA/en unknown
- 2016-02-04 CR CR20170359A patent/CR20170359A/es unknown
- 2016-02-04 JP JP2017541089A patent/JP2018505676A/ja active Pending
- 2016-02-04 US US15/016,169 patent/US10799523B2/en active Active
- 2016-02-04 MX MX2017010066A patent/MX2017010066A/es unknown
- 2016-02-04 CN CN201680019681.3A patent/CN107922946A/zh active Pending
- 2016-02-04 US US15/549,021 patent/US11077132B2/en active Active
- 2016-02-04 EP EP16706943.4A patent/EP3253875B1/en active Active
- 2016-02-04 RU RU2017127609A patent/RU2017127609A/ru not_active Application Discontinuation
- 2016-02-04 BR BR112017016663A patent/BR112017016663A2/pt not_active Application Discontinuation
- 2016-02-04 AU AU2016215155A patent/AU2016215155A1/en not_active Abandoned
- 2016-02-04 KR KR1020177024109A patent/KR20180016970A/ko unknown
- 2016-02-04 WO PCT/US2016/016646 patent/WO2016126995A1/en active Application Filing
- 2016-02-04 TW TW105103800A patent/TW201641691A/zh unknown
- 2016-02-04 EP EP19214990.4A patent/EP3653712B1/en active Active
- 2016-02-04 PE PE2017001323A patent/PE20171766A1/es unknown
- 2016-02-04 CA CA2975525A patent/CA2975525A1/en not_active Abandoned
- 2016-02-04 UY UY0001036550A patent/UY36550A/es unknown
- 2016-02-04 MA MA041586A patent/MA41586A/fr unknown
- 2016-02-04 DK DK16706943.4T patent/DK3253875T3/da active
-
2017
- 2017-07-27 ZA ZA2017/05119A patent/ZA201705119B/en unknown
- 2017-07-30 IL IL253730A patent/IL253730A0/en unknown
- 2017-08-01 CL CL2017001956A patent/CL2017001956A1/es unknown
- 2017-08-03 PH PH12017550069A patent/PH12017550069A1/en unknown
- 2017-09-01 CO CONC2017/0009008A patent/CO2017009008A2/es unknown
-
2018
- 2018-06-12 HK HK18107636.5A patent/HK1248276A1/zh unknown
-
2021
- 2021-07-02 US US17/367,242 patent/US20220143064A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10799523B2 (en) | 2020-10-13 |
CL2017001956A1 (es) | 2018-06-01 |
US20180161356A1 (en) | 2018-06-14 |
SG11201706293XA (en) | 2017-09-28 |
EP3653712A1 (en) | 2020-05-20 |
BR112017016663A2 (pt) | 2018-04-10 |
US20220143064A1 (en) | 2022-05-12 |
AU2016215155A1 (en) | 2017-08-17 |
UY36550A (es) | 2016-08-31 |
ZA201705119B (en) | 2020-01-29 |
US20160237427A1 (en) | 2016-08-18 |
EP3253875A1 (en) | 2017-12-13 |
IL253730A0 (en) | 2017-09-28 |
TW201641691A (zh) | 2016-12-01 |
CA2975525A1 (en) | 2016-08-11 |
CR20170359A (es) | 2017-11-24 |
RU2017127609A (ru) | 2019-03-04 |
MX2017010066A (es) | 2017-11-01 |
EP3653712B1 (en) | 2022-11-30 |
CO2017009008A2 (es) | 2017-11-21 |
CN107922946A (zh) | 2018-04-17 |
EP3253875B1 (en) | 2020-01-08 |
HK1248276A1 (zh) | 2018-10-12 |
JP2018505676A (ja) | 2018-03-01 |
WO2016126995A1 (en) | 2016-08-11 |
MA41586A (fr) | 2017-12-13 |
US11077132B2 (en) | 2021-08-03 |
PH12017550069A1 (en) | 2018-02-05 |
PE20171766A1 (es) | 2017-12-21 |
KR20180016970A (ko) | 2018-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3253875T3 (da) | Tau-antisense-oligomerer og anvendelser deraf | |
DK3872085T3 (da) | Stam-virussekvenser og anvendelser heraf | |
DK3368534T3 (da) | Valbenazin-ditosylat og polymorfer deraf | |
DK3322804T3 (da) | Nuklease-uafhængigt målrettet genredigeringsplatform og anvendelser deraf | |
DK3265947T3 (da) | Fremgangsmåde og system til kryptering | |
DK3888658T3 (da) | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil | |
DK3157552T3 (da) | Syntac-polypeptider og anvendelser deraf | |
DK3218358T3 (da) | Ifluorometyl-aminopyridiner og difluorometyl-aminopyrimidiner | |
DK3308111T3 (da) | Belastningsføler og belastningsføler-anlæg | |
DK3265571T3 (da) | Fler-vektorsystem og anvendelse heraf | |
DK2980328T3 (da) | Nedsivningsblokelement, nedsivningsblok og transportenhed | |
DK3244946T3 (da) | Infusionsindretningssystem og anordning | |
DK3227237T3 (da) | Indretning og anvendelse deraf til uv-bearbejdning af fluider | |
DK3524301T3 (da) | Kanyleenhed med kanylehylster og bevægelig kanyleunderstøtning | |
DK3346056T3 (da) | Rengøringssystem og fremgangsmåde | |
DK3265641T3 (da) | Stigørenhed og fremgangsmåde | |
DK3161139T3 (da) | Tlr-4-specifikke aptamerer og anvendelser heraf | |
DK3209773T3 (da) | Prolintolerante tripeptidylpeptidaser og anvendelser deraf | |
DK2963077T3 (da) | Hydrofile blokcopolymere og deraf fremstillede membraner | |
DK3128005T3 (da) | Sirp-alfa-variantkonstruktioner og anvendelser deraf | |
DK3316951T3 (da) | Eyewear and flexible elements | |
DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
DK3337506T3 (da) | Kombinationer og anvendelser deraf | |
DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
DK3321279T3 (da) | Exenatidmodificeringsmiddel og anvendelse deraf |